Lawmakers are expected to grill CMS Deputy Administrator Sean Cavanaugh on Thursday about a Medicare reimbursement policy, opposed by members of both parties , designed to drive down prices of biosimilars. FDA drug center Director Janet Woodcock is also slated to testify at the Feb. 4 Energy & Commerce hearing on biosimilars. The committee is holding the hearing to get an update on the Affordable Care Act's approval path for biosimilars. The background memorandum for the hearing indicates that committee...